These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15607376)

  • 1. CML cytogenetic relapse after cessation of imatinib therapy.
    Usuki K; Iijima K; Iki S; Urabe A
    Leuk Res; 2005 Feb; 29(2):237-8. PubMed ID: 15607376
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
    Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C
    Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
    [No Abstract]   [Full Text] [Related]  

  • 4. Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
    Oku E; Imamura R; Nagata S; Takata Y; Seki R; Otsubo K; Hashiguchi M; Osaki K; Yakushiji K; Yoshimoto K; Ogata H; Sata M; Okamura T
    Acta Haematol; 2007; 117(4):191-6. PubMed ID: 17170522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 7. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
    Moser AM; Manor E; Narkis G; Kapelushnik J
    Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
    Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the response to imatinib in chronic myeloid leukemia patients--comparison between the FISH, multiplex and RT-PCR methods.
    Raanani P; Ben-Bassat I; Gan S; Trakhtenbrot L; Mark Z; Ashur-Fabian O; Itskovich S; Brok-Simoni F; Rechavi G; Amariglio N; Nagler A
    Eur J Haematol; 2004 Oct; 73(4):243-50. PubMed ID: 15347310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 15. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M; Ristic S; Pavlovic S; Colovic M
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57.
    Kreuzer KA; le Coutre P
    Haematologica; 2004 Aug; 89(8):ELT12. PubMed ID: 15339701
    [No Abstract]   [Full Text] [Related]  

  • 18. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
    Kiguchi T; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
    Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
    J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.